Compared with whom? Addressing the prognostic value of ambulatory blood pressure categories by Verdecchia, Paolo et al.
Compared With Whom?
Addressing the Prognostic Value of Ambulatory Blood Pressure Categories
Paolo Verdecchia, Fabio Angeli, Jan A. Staessen
Two statisticians meet.
How do you do?
How do I do? Compared to whom?
—Anonymous
In several longitudinal studies in the general population1–4and referred cohorts of hypertensive patients,5,6 ambula-tory blood pressure (BP) proved superior to clinic BP for
prediction of the risk of major cardiovascular events and mor-
tality. These studies analyzed ambulatory BP as a continuous
variable.1–6 However, for risk stratification and management of
patients, clinicians need operational thresholds, which, by defi-
nition, are somewhat arbitrary.
Indeed, several clinical categories based on ambulatory BP
have been proposed over the last 2 decades well before the
evidence of the prognostic superiority of ambulatory over
clinic BP as continuous variables became clear. “White-coat”
hypertension (WCH), “masked” hypertension, “nondipping,”
“overdipping,” and “early morning rise” BP patterns are
examples of clinical categories of which the prognostic value
has been investigated in outcome-based studies.
Compared With Whom?
When addressing the prognostic value of a given clinical
category, it is crucial that the reference group be clearly
defined. Albeit apparently obvious, the conclusion that a
given category is a condition of “increased,” “unchanged,” or
“decreased” risk must require a precise and clinically appli-
cable definition of the control group.
For example, the prognostic impact of WCH, broadly
defined by the coexistence of elevated clinic BP with a
normal ambulatory BP, has been addressed in some outcome-
based studies. The majority of these studies7 examined
cohorts of referred hypertensive subjects and compared the
group with WCH either with subjects with higher ambulatory
BP (ambulatory or sustained hypertension) or with healthy
normotensive subjects, taken as a reference group.
Importantly, in most of these studies, no attempts were
made to further subdivide the normotensive subjects into
those with normal and those with elevated ambulatory BP.
The underlying reason seems quite obvious: if ambulatory BP
is intended as a diagnostic tool to improve risk stratification
in clinically hypertensive subjects, the “no-added-risk” group
should include the totality of clinically normotensive subjects
for whom there is universal evidence that clinic BP is a
fundamental determinant of outcome.
By contrast, if ambulatory BP is intended as a potential tool
to improve risk stratification in the general population, the
attempt to divide those with normal from those with elevated
ambulatory BP in the normotensive group becomes justified.
There is growing evidence that clinically normotensive sub-
jects with elevated ambulatory BP (masked hypertension)
have greater organ damage and a higher incidence of cardio-
vascular events than those with normal ambulatory BP.8 This
supports the practice of subclassifying the clinically normo-
tensive subjects on the basis of their level of ambulatory BP.
For the time being, it seems reasonable to speculate that any
implication regarding the clinical use of ambulatory BP as
coming out from general population studies with stratification of
clinically normotensive by ambulatory BP categories remains
applicable to the general population, not necessarily to referred
cohorts of subjects with clinical hypertension.
Consistent with this line of thinking should be the inter-
pretation of a report from the Pressioni Arteriose Monitorate
e Loro Associazioni (PAMELA) Study published in this issue
of Hypertension.9 This article is an extension of a previous
report from the PAMELA Study, which addressed the prog-
nostic impact of clinic and ambulatory BP as continuous
variables. Here, the authors made multiple comparisons of
subjects with normal and abnormal values defined by clinic
BP, 24-hour ambulatory BP, and self-measured home BP.
Cardiovascular and all-cause mortality were the outcome
measures. Similarly to other general population studies, the
clinically normotensive subjects with elevated 24-hour am-
bulatory BP or home BP were not included in the normoten-
sive (reference) group, but in the distinct category of masked
hypertension. Notably, prevalence of these subjects in the
total population was 15%.
Although only summary percentages, not actual numbers,
of cardiovascular events were provided, and although the
hazard ratios (HRs) for cardiovascular events in the different
ambulatory BP categories were not reported as actual num-
bers but only displayed graphically, the most remarkable
finding of this report was the increased risk of cardiovascular
mortality in the 2 groups with WCH and masked hyperten-
sion as compared with the normotensive reference group, regard-
The opinions expressed in this editorial are not necessarily those of the
editors or of the American Heart Association.
From the Dipartimento Malattie Cardiovascolari (P.V., F.A.), Ospedale R.
Silvestrini, Perugia, Italy; and Laboratory of Hypertension (J.A.S.), Depart-
ment of Cardiovascular Disease, University of Leuven, Campus Gasthuisberg,
Leuven, Belgium.
Correspondence to Paolo Verdecchia, Dipartimento Malattie Cardio-
vascolari, Ospedale R. Silvestrini, Localita` S. Andrea delle Fratte, 06132
Perugia, Italy. E-mail verdec@tin.it
(Hypertension. 2006;47:820-821.)
© 2006 American Heart Association, Inc.
Hypertension is available at http://www.hypertensionaha.org
DOI: 10.1161/01.HYP.0000215364.56025.b9
820
Editorial Commentary
less of whether the diagnoses of WCH and masked hypertension
were based on 24-hour ambulatory or self-measured BP.
Different results have been obtained by Ohkubo et al10 in a
general population study from Japan and by Fagard et al11 in
a general practice in Belgium. In the study from Japan,10 the
risk of cardiovascular mortality did not differ between the
normotensive control group, from which the subjects with
masked hypertension had been excluded, and the group with
WCH (HR, 1.54; 95% confidence interval [CI], 0.73 to 3.21).
Also, the risk of stroke (HR, 1.07; 95% CI, 0.58 to 2.07) and
that of cardiovascular mortality and stroke combined (HR,
1.28; 95% CI, 0.76 to 2.14) did not differ between the
normotensive control group and the group with WCH. When
compared with the normotensive subjects, those with masked
hypertension showed an increased risk of stroke (HR, 2.17;
95% CI, 1.31 to 3.60) but not of cardiovascular mortality
(HR, 1.88; 95% CI, 0.95 to 3.72). In the study from
Belgium,11 the risk of cardiovascular events was not dissim-
ilar in the normotensive control group, the group with WCH,
and that with masked hypertension. An excess risk of events
was noted only in the subset with ambulatory (sustained)
hypertension.
Further studies should clarify the clinical value of ambu-
latory and home BP in the general population. An important
caveat to consider, however, is that the exclusion of subjects
with masked hypertension from the normotensive control
group may be expected to produce some reduction in the
overall level of risk in this selected group. Consequently,
caution is needed when comparing the results of population
studies from those obtained in hypertensive patients in which
the normotensive control group has been analyzed as a whole,
with inclusion of the subjects with masked hypertension.
Conclusions
Context and interpretation of clinical research focused on the
potential value of 24-hour ambulatory BP and home BP for
identification of masked hypertension in clinically normoten-
sive subjects should be maintained distinct from that aimed at
clarifying the clinical place of 24-hour ambulatory BP and
home BP in subjects with traditional diagnosis of hyperten-
sion. How to make the best use of BP categories defined by
ambulatory and home BP in subjects with clinical hyperten-
sion is still a topic for discussion and research. At present, it
seems reasonable to suggest that any “normotensive control
group” included in this kind of research should include the
totality of clinically normotensive subjects. By contrast, the
growing research area regarding masked hypertension may
greatly benefit from general population studies and even
studies in 100% clinically normotensive populations.
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